Angel Adegbesan

New York

Reporter at Bloomberg News

Stocks reporter @business. Alum at @newmarkjschool and @yorkcollegecuny

Featured in: Favicon

bloomberg.com Favicon

washingtonpost.com Favicon

time.com

yahoo.com (+10) Favicon

latimes.com Favicon

smh.com.au Favicon

chicagotribune.com Favicon

ndtv.com

thestar.com Favicon

chron.com + 87 more

Articles

Why One Wall Street Analyst Bravely Downgraded UnitedHealth in February

2 weeks ago | bloomberg.com | Angel Adegbesan

Hi, all, it’s Angel in New York, where I report on health-care stocks. One company has been the source of much drama in recent months. But before I explain …Through much of 2024, UnitedHealth Group was flying high. The largest US health insurer by membership had posted years of double-digit revenue growth. Its shares hit a record high in November.
UnitedHealth’s Plunge Blindsided Analysts Across Wall Street (2)

2 weeks ago | news.bloombergtax.com | Angel Adegbesan

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
UnitedHealth Plunge Stunned Wall Street. One Analyst Saw It Coming

2 weeks ago | bloomberg.com | Angel Adegbesan

(Bloomberg) -- When CFRA’s Paige Meyer slapped a “sell” rating on UnitedHealth Group Inc. in February, she was the lone analyst out of 30 tracked by Bloomberg with a negative view of the company. Meyer’s price target implying a 22% fall for the shares glared in a sea of optimistic forecasts, while her warnings on regulatory uncertainty and high medical expenses seemed almost alarmist.
UnitedHealth Plunge Stunned Wall Street. One Analyst Saw It Coming

2 weeks ago | yahoo.com | Angel Adegbesan

(Bloomberg) -- When CFRA’s Paige Meyer slapped a “sell” rating on UnitedHealth Group Inc. in February, she was the lone analyst out of 30 tracked by Bloomberg with a negative view of the company. Most Read from BloombergAdvertisementAdvertisementMeyer’s price target implying a 22% fall for the shares glared in a sea of optimistic forecasts, while her warnings on regulatory uncertainty and high medical expenses seemed almost alarmist.
UnitedHealth Plunge Stunned Wall Street. One Analyst Saw It Coming

2 weeks ago | advisorperspectives.com | Angel Adegbesan

When CFRA’s Paige Meyer slapped a “sell” rating on UnitedHealth Group Inc. in February, she was the lone analyst out of 30 tracked by Bloomberg with a negative view of the company. Meyer’s price target implying a 22% fall for the shares glared in a sea of optimistic forecasts, while her warnings on regulatory uncertainty and high medical expenses seemed almost alarmist.
Novavax Shares Advance as FDA Approves Covid Vaccine Use (1)

2 weeks ago | news.bloombergtax.com | Angel Adegbesan

(Updates with shares, analysts’ comments.)Novavax shares rally 18% in premarket trading after the US FDA approved the drugmaker’s Covid-19 vaccine for adults 65 years and older as well as those aged 12 to 64 years who have at least one medical condition that puts them at a higher risk of severe illness from Covid.
Novavax Shares Advance as FDA Approves Covid Vaccine Use (1)

2 weeks ago | news.bloomberglaw.com | Angel Adegbesan

shares rally 18% in premarket trading after the US FDA approved the drugmaker’s Covid-19 vaccine for adults 65 years and older as well as those aged 12 to 64 years who have at least one medical condition that puts them at a higher risk of severe illness from Covid. • Shares of peer vaccine maker are up 3.2% before the open• Jefferies, (buy)• Says the approval enables immediate commercial entry for 2025/2026 season under partner Sanofi’s lead and unlocks $175 million milestone payments
Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut

4 weeks ago | bloomberg.com | Angel Adegbesan

The Sarepta Therapeutics headquarters in Cambridge, Massachusetts, in 2019. (Bloomberg) -- Sarepta Therapeutics Inc. capped its worst week in four years as disappointing earnings and regulatory fears hit the drugmaker’s shares. The pain started Tuesday, when Sarepta sank 27% after the commissioner for the Food and Drug Administration named a new regulator that was seen as a vocal critic of the company and its lead medicine, Elevidys.
Gene Therapy Makers Rise as FDA Makary Comments Seen as Positive

1 month ago | news.bloombergtax.com | Angel Adegbesan

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Gene Therapy Makers Rise as FDA Makary Comments Seen as Positive

1 month ago | news.bloomberglaw.com | Angel Adegbesan

Makers of gene therapies and drugs for rare diseases are rallying on Monday after FDA Commissioner commented on drug approvals in an interview over the weekend that analysts view as positive for the sector. • RBC Capital Markets,• Notes Makary remains a proponent of expedited drug approvals and his comments suggest he “may not dramatically break from this trend of biomarker-based accelerated approvals followed by confirmatory studies”• This is potentially positive for “PTCT, SRPT, ...